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Serum Antibodies against Human Intracisternal A-type Particle
(HIAP) Endogenous Retrovirus in Alopecia Areata Patients:
A Hallmark of Autoimmune Disease?
To the Editor:
Several studies have demonstrated the presence of actively
replicating human endogenous retroviruses associated with
various autoimmune disorders (Perron and Seigneurin,
1999; Portis, 2002), in particular, Sjo¨grens’s syndrome,
rheumatoid arthritis, type 1 or insulin-dependent diabetes
mellitus, multiple sclerosis, systemic lupus erythematosus,
and systemic sclerosis. Serum antibodies specific for
human intracisternal A-type particles (HIAP), a human endo-
genous retrovirus recognized by monoclonal antibody
against HIV-1 p24 capsid protein (Garry et al, 1990), have
been detected significantly in association with primary
biliary cirrhosis (Mason et al, 1998) and systemic sclerosis
(La Placa et al, 2004).
Alopecia areata (AA) is a non-scarring hair disorder of
unknown etiology. Various hypotheses have been involved
in the pathogenesis of AA, including environmental, and
psychological factors, but all these observations remain
inconsistent (Duvic et al, 2001). An exogenous viral infection
has also been postulated by some authors (Skinner et al,
1995), but the results have not been confirmed by other
studies (Tosti et al, 1996). Genetic factors have been linked
to disease susceptibility and severity (Duvic et al, 2001).
Current evidence suggests that AA is an autoimmune
disease, due to an aberrant T cell response against hair
follicle self-antigens (McElwee et al, 1999; Kalish and Gilhar,
2003; Hordinsky and Ericson, 2004).
The aim of our study was to evaluate the presence of
serum antibody reactivity to HIAP proteins in patients
affected by AA.
A total of 34 serum samples from patients with AA, and
20 control serum samples from healthy subjects, were
examined. All the sera were collected between October
2002 and July 2003, after obtaining informed consent, and
stored at 801C, without preservatives, until use. AA pati-
ents enrolled in the study included 14 male and 20 female
subjects (age range: 10–60 y; median age 29.7). All patients
fulfilled the AA diagnostic criteria as described in the
literature (Duvic et al, 2001). In particular, 23 were affected
by alopecia universalis, with total scalp and body hair loss,
and 11 patients had alopecia totalis, with total scalp hair
loss without body involvement. The duration of disease was
between 1 and 12 y, with a median duration of 2.8 y. All
patients included in the study were HIV-1/2 negative and
HTLV–I and II negative (HIV Blot 2.2 Genelabs Diagnostics,
Singapore; HTLV I/II Immunoblot, Cambridge Biotech,
Worchester, Massachusetts), and none was affected by
any other autoimmune disorder. Records of atopy were
present in the anamnesis of 11 patients. Healthy controls
were represented by 8 male and 12 female blood donors
(age range: 19–45 y; median age 27.5).
Serum antibody reactivity to HIAP proteins was studied
by western blot (immunoblot) analysis performed as
previously described (La Placa et al, 2004). Briefly,
uninfected and HIAP-infected RH9/MC lymphoblastoid
cells were obtained from the Cell Culture Collection Center
of the Istituto Zooprofilattico Sperimentale di Brescia
(Brescia, Italy) and grown in RPMI medium (GIBCO, Grand
Island, New York) plus 10% fetal calf serum. The micro-
somal fraction was obtained, from both types of cell
cultures, by disruption of cells in a hypotonic buffer followed
by sucrose density gradient ultracentrifugation. Microsomal
fraction proteins were resolved by sodium dodecyl sulfate/
12% polyacrylamide gel electrophoresis and blotted onto
nitrocellulose strips. Nitrocellulose strips were incubated
overnight, at room temperature, in the presence of 2 mL of
blotting buffer (Genelabs Diagnostics) containing 20 mL of
serum sample. Nitrocellulose strips were then washed
and further incubated for 1 h at room temperature with
peroxidase-conjugated anti-human IgG rabbit serum (Sig-
ma, Milan, Italy) in PBS containing 1% of bovine serum
albumin, and specific results were revealed by employing
enhanced chemiluminescent western blotting detection
reagents (Amersham, Arlington Heights, Illinois). All the sera
were tested with immunoblots from both HIAP-infected and
uninfected cells, to assess specific reactivity to HIAP
proteins, and all the tests were performed in duplicate, to
check reproducibility. HIAP immunoblots were considered
positive when serum samples reacted with one or more
proteins with electrophoretic mobility corresponding to that
of known HIAP proteins (p17, p24, p30, p46, p60, p80, p84,
p97). In addition, all sera were screened for anti-thyroid
antibodies and antinuclear antibodies (ANA) including
anti-centromere IgG antibodies (evaluated by microscopy
with an image analyzer, after indirect immunofluorescence
on commercially available tissue slides—Kallenstad/
Sanofi Diagnostic Pasteur, Chaska, Minnesota), and various
extractable nuclear antigens (ENAs) including Scl-70,
Ro(SS-A), La(SS-B), Sm, U1-nRNP, and Jo-1, using stan-
dard procedures with a commercially available reagent
kit (ProfilePlus, Euroimmun GmbH, Lubeck, Germany).
Abbreviations: AA, alopecia areata; HIAP, human intracisternal
A-type particle
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Statistical analysis of the data was performed utilizing the
Fisher Exact Test.
None of the sera examined showed the presence of
autoantibodies reacting with thyroid antigens, ANA or ENAs.
Western blot reactivity to one or more HIAP proteins was
repeatedly detected in 25 of 34 (73.5%) AA patients, and
only in two of 20 (10%) blood donors (p¼0.0009). In
particular, most of the HIAP-positive AA serum samples
reacted against p30 (14 samples), p46 (23 samples), and
p60 (11 samples). None of the sera examined showed the
presence of antibody reactivity against proteins resolved
from the microsomal fraction of HIAP-uninfected RH9 cells.
Representative immunoblot results are illustrated in Fig 1.
The data obtained in the entire population examined are
summarized in Tables I and II.
The results of our study, obtained from reproducible and
specific immunoblot analyses, demonstrated the presence
of serum antibody against HIAP endogenous retrovirus
proteins in a significantly (p¼ 0.0009) high percentage
(73.5%) of AA patients. None of the HIAP-positive samples
had immunoblot serum reactivity against microsomal
fraction proteins from the uninfected cell line, thus
demonstrating the absolute specificity of immunoblot serum
reactivity against HIAP-infected cell microsomal proteins.
It is not easy, however, to assess definitely the
etiopathogenetic significance of the findings of our study,
and more especially, to assess if the activation of an
endogenous retrovirus such as HIAP may be somehow
related to the outcome of AA. Exactly which antigens are
actually involved in inducing an HIAP-reacting antibody
response remains an open question. The presence of IgG
antibody reactivity to HIAP proteins may, in fact, be either
attributable to the presence of an autoimmune response to
antigenically related cellular proteins, or to the production of
largely cross-reacting antibodies due to the immune
dysregulation associated with autoimmune disease. Alter-
natively, the expression of HIAP proteins, and the conse-
quent induction of a specific immune response, might be
merely the result of incidental HIAP activation induced by
attendant pathological processes.
In conclusion, our study has shown that the presence of
serum antibodies reacting with human intracisternal A-type
(HIAP) retrovirus proteins is significantly associated with AA.
Whether these results indicate the possible involvement of
HIAP endogenous retrovirus in the origin and development
of AA is still an open question. There is, however, a growing
body of evidence suggesting that serum antibodies to
endogenous retrovirus proteins might be considered a
hallmark of a large array of autoimmune diseases and our
findings indicate that AA should also be included in this
group of disorders. Increased and concerted research
efforts are required to clarify definitively the meaning of
anti-endogenous retrovirus protein antibody response in the
etiopathogenesis of AA and other autoimmune pathologies.
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Figure 1
Representative results of western blot analysis of the presence of
antibodies against HIAP proteins in serum samples from AA
patients and healthy controls (blood donors). Lanes 1–16: HIAP-
positive AA patients. Lanes 17–19: HIAP-negative control subjects
(blood donors). Lane 20: serum sample reacting with only one HIAP
protein.
Table I. Western blot antibody reactivity to human intracister-
nal A-type particles (HIAP) proteins in serum samples from
alopecia areata (AA) patients and control healthy blood donor
(BD) subjects
Serum
samples
Number of sera
examined
Number and
percentage of sera
reacting with one
or more HIAP
proteins
AA patients 34 25 (73.5%)
BD subjects 20 2 (10.0%)
Table II. Western blot antibody reactivity against individual
human intracisternal A-type particles (HIAP) proteins in
serum samples from alopecia areata (AA) patients and
healthy controls
HIAP proteins,
listed according
to molecular weight
Number and
percentage of
AA patient sera
reacting with
each HIAP protein
Number and
percentage of
healthy control
sera reacting with
each HIAP protein
p17 5 (14.7%) –
p24 5 (14.7%) 1 (5.0%)
p30 14 (41.1%) –
p46 23 (67.6%) 1 (5.0%)
p60 11 (32.3%) –
p80 1 (2.9%) 1 (5.0%)
p84 1 (2.9%) –
p97 – –
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